14-day Premium Trial Subscription Sign Up For FreeGet Free

When Should You SELL Your Stocks? Click to watch.

Akebia Therapeutics Stock Forecast

NASDAQ:AKBA BUY SELL

$0.35 (3.47%)

Volume: 6.913M

Closed: May 19, 2022

Hollow Logo Score: -4.801

Akebia Therapeutics Stock Forecast

BUY SELL NASDAQ:AKBA
$0.35 (3.47%)

Volume: 6.913M

Closed: May 19, 2022

Score Hollow Logo -4.801

Akebia Therapeutics Stock Forecast NASDAQ:AKBA

Price Target and Analyst Ratings

Historical Ratings

Date Upside / Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
2022-05-16 257.14% HC Wainwright & Co. $2.00 $1.25 Maintains Neutral
2022-03-31 471.43% Piper Sandler $8.00 $2.00 Downgrades Overweight Neutral
2022-03-31 471.43% Mizuho $6.00 $2.00 Downgrades Buy Neutral
2022-03-31 - Needham - Downgrades Buy Hold
2022-03-31 471.43% HC Wainwright & Co. $10.00 $2.00 Downgrades Buy Neutral
2021-11-11 2757.14% HC Wainwright & Co. $6.00 $10.00 Maintains Buy
2021-03-08 2185.71% Cantor Fitzgerald $8.00 Initiates Coverage On Overweight
2021-03-08 1614.29% HC Wainwright & Co. $9.00 $6.00 Maintains Buy
2021-01-29 - JP Morgan - Downgrades Neutral Underweight
2020-10-26 2471.43% HC Wainwright & Co. $10.00 $9.00 Maintains Buy
2020-09-04 2757.14% HC Wainwright & Co. $17.00 $10.00 Maintains Buy
2020-09-04 1614.29% BTIG $26.00 $6.00 Maintains Buy
2020-09-04 757.14% Morgan Stanley $12.00 $3.00 Maintains Equal-Weight
2020-07-15 3328.57% Morgan Stanley $11.00 $12.00 Maintains Equal-Weight
2020-05-06 5042.86% JP Morgan $13.00 $18.00 Maintains Overweight
2020-05-06 3042.86% Morgan Stanley $9.00 $11.00 Maintains Equal-Weight
2020-05-06 4757.14% HC Wainwright & Co. $16.00 $17.00 Maintains Buy
2020-05-06 4757.14% Mizuho $15.00 $17.00 Maintains Buy
2020-05-05 5042.86% Needham $15.00 $18.00 Maintains Buy
2020-03-11 4185.71% Mizuho $16.00 $15.00 Reiterates Buy
2020-02-20 3614.29% JP Morgan $10.00 $13.00 Maintains Overweight
2019-11-18 4471.43% HC Wainwright & Co. $17.00 $16.00 Maintains Buy
2019-08-06 4757.14% HC Wainwright & Co. $19.00 $17.00 Maintains Buy

AKBA Stock Trend

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled.

Due to the high volatility and the trend direction we are not able to give forecast range for this stock. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Data

Date Bottom Mid Top
2022-05-23 $-0.58 $-0.0038 $0.57
2022-05-24 $-0.62 $-0.0501 $0.52
2022-05-25 $-0.67 $-0.0964 $0.48
2022-05-26 $-0.72 $-0.14 $0.43
2022-05-27 $-0.76 $-0.19 $0.38
2022-05-31 $-0.81 $-0.24 $0.34
2022-06-01 $-0.85 $-0.28 $0.29
2022-06-02 $-0.90 $-0.33 $0.24
2022-06-03 $-0.95 $-0.37 $0.20
2022-06-06 $-0.99 $-0.42 $0.15
2022-06-07 $-1.04 $-0.47 $0.11
2022-06-08 $-1.09 $-0.51 $0.0595
2022-06-09 $-1.13 $-0.56 $0.0132
2022-06-10 $-1.18 $-0.61 $-0.0331
2022-06-13 $-1.22 $-0.65 $-0.0794
2022-06-14 $-1.27 $-0.70 $-0.13
2022-06-15 $-1.32 $-0.74 $-0.17
2022-06-16 $-1.36 $-0.79 $-0.22
2022-06-17 $-1.41 $-0.84 $-0.26
2022-06-21 $-1.46 $-0.88 $-0.31
2022-06-22 $-1.50 $-0.93 $-0.36
2022-06-23 $-1.55 $-0.98 $-0.40
2022-06-24 $-1.60 $-1.02 $-0.45
2022-06-27 $-1.64 $-1.07 $-0.50
2022-06-28 $-1.69 $-1.11 $-0.54
2022-06-29 $-1.73 $-1.16 $-0.59
2022-06-30 $-1.78 $-1.21 $-0.63
2022-07-01 $-1.83 $-1.25 $-0.68
2022-07-05 $-1.87 $-1.30 $-0.73
2022-07-06 $-1.92 $-1.35 $-0.77

About Akebia Therapeutics

Akebia Therapeutics Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is ... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!
.

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT